Mouse IgG3 Isotype Control - Purified In vivo PLATINUM Functional Grade

Antibody Details

Product Details

Host Species

Mouse

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

< 0.5 EU/mg as determined by the LAL method

Purity

≥98% monomer by analytical SEC

⋅

> 95% by SDS Page

Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Storage and Handling

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Country of Origin

USA

Working Concentration

This isotype control antibody should be used at the same concentration as the primary antibody.

RRID

AB_2894258

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

This Mouse IgG₃ isotype control antibody has been tested against selected species' cells and tissues to assure minimal cross reactivity.

Antigen Details

Protein

T-bet

PubMed

T-bet

References & Citations

1. Wright, TM et al. (2001) Arthritis Rheum. 44(7):1654-9. PubMed

2. Nishikawa, Takeji et al. (2000) Journal of Investigative Dermatology
114(1): 88-94. PubMed